Two nanotechnology white papers released.

The article reports that NanoMarkets LC has announced the release of two white papers that address the role of nanotechnology in drug discovery and drug delivery. As the pharmaceutical industry matures, meeting Wall Street's aggressive growth expectations becomes increasingly difficult. Many companies will continue to grow via merger and acquisition activity and through internal development of high-value compounds. Nonetheless, over the next decade, several blockbuster drugs will go off patent, resulting in an estimated loss of $30-$40 billion in annual product revenues as generic drugs enter the market. This change is accelerating the industry's constant need to "build the pipeline" of new compounds, and to rapidly enter new markets.